ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
- Conditions
- Hypophosphatasia
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT02496689
- Locations
- 🇺🇸
Colorado Center for Bone Research, Lakewood, Colorado, United States
🇫🇷Hôpital Necker - Enfants Malades, Paris, France
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
- Conditions
- Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT02376751
A Study to Identify and Characterize LAL-D Patients in High-risk Populations
Terminated
- Conditions
- Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 640
- Registration Number
- NCT02345421
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
Phase 3
Completed
- Conditions
- Bleeding
- Interventions
- Biological: Andexanet
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 479
- Registration Number
- NCT02329327
- Locations
- 🇬🇧
Clinical Study Site, Stoke on Trent, United Kingdom
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02324049
Registry of Patients With Hypophosphatasia
- Conditions
- Hypophosphatasia (HPP)
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT02306720
- Locations
- 🇬🇧
Research Site, Belfast, United Kingdom
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Phase 3
Completed
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Biological: EculizumabDrug: Placebo
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT02301624
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
Terminated
- Conditions
- MPS IIIB (Sanfilippo B Syndrome)
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02293408
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Completed
- Conditions
- MPS IIIB (Sanfilippo Syndrome)
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02293382
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02273596
- Locations
- 🇬🇧
Clinical Trial Site, Birmingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath